Direct Links to important GMP API Guidelines

FDA Guidance for Industry: Completeness Assessments for Type II API DMFs under GDUFA

This guidance is intended for holders of Type II active pharmaceutical ingredient (API) drug master files (DMFs) that are or will be referenced in an abbreviated new drug application (ANDA), an amendment to an ANDA, a prior approval supplement (PAS) to an ANDA, or an amendment to a PAS (generic drug submissions).

more

Eudralex Volume 3 Quality Working Party questions and answers on API mix

This document provides information on how mixtures of active pharmaceutical ingredient and excipients (API mix) are considered in a marketing authorisation procedure.

more

ICH E2A CLINICAL SAFETY DATA MANAGEMENT: DEFINITIONS AND STANDARDS FOR EXPEDITED REPORTING

This document gives standard definitions and terminology for key aspects of clinical safety reporting. It also gives guidance on mechanisms for handling expedited (rapid) reporting of adverse drug reactions in the investigational phase of drug development.

more

APIC - GUIDANCE ON ASPECTS OF CLEANING VALIDATION IN ACTIVE PHARMACEUTICAL INGREDIENT PLANTS

The document reflects the outcome of discussions between APIC member companies on how cleaning validation requirements could be fulfilled and implemented as part of routine operations.

more

Auditing Guide - Annex 1 – Pre-Audit Questionnaire

The purpose of this questionnaire is to facilitate the preparation of the auditors for the audit at the API manufacturer's site.

more

Auditing Guide - Annex 3 – Audit Report Template

This template provides a standard for reports fo audits conducted within the framework of the APIC Audit Program.

more

ICH Q11 Guideline: Development and Manufacture of Drug Substances (Chemical Entities and Biotechnological/Biological Entities) Questions and Answers

This document provides clarification to improve harmonisation of the considerations for the selection and justification of starting materials for API syntheses.

more

APIC - Statement on Good distribution practices

more

APIC - Quality Agreement for Laboratories; Guideline and Templates

more

Human Gene Therapy for Hemophilia - Guidance for Industry

Dieser Leitfaden enthält Empfehlungen für Sponsoren, die humane Gentherapie (GT)1-Produkte für die Behandlung von Hämophilie entwickeln, einschließlich des Designs klinischer Studien und der damit verbundenen Entwicklung von Gerinnungsfaktor VIII (Hämophilie A) und IX (Hämophilie B) Aktivitätsprüfungen, einschließlich der Frage, wie Diskrepanzen zwischen Faktor VIII und Faktor IX Aktivitätsprüfungen beseitigt werden können. Dieser Leitfaden enthält auch Empfehlungen zu präklinischen Überlegungen zur Unterstützung der Entwicklung von GT-Produkten zur Behandlung von Hämophilie.

more

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK